| pubmed-article:8205224 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8205224 | lifeskim:mentions | umls-concept:C0027078 | lld:lifeskim |
| pubmed-article:8205224 | lifeskim:mentions | umls-concept:C0302912 | lld:lifeskim |
| pubmed-article:8205224 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:8205224 | pubmed:dateCreated | 1994-7-14 | lld:pubmed |
| pubmed-article:8205224 | pubmed:abstractText | The addition of 25 microM hydrogen peroxide to 20 microM metmyoglobin produces ferryl (FeIV = O) myoglobin. Optical spectroscopy shows that the ferryl species reaches a maximum concentration (60-70% of total haem) after 10 minutes and decays slowly (hours). Low temperature EPR spectroscopy of the high spin metmyoglobin (g = 6) signal is consistent with these findings. At this low peroxide concentration there is no evidence for iron release from the haem. At least two free radicals are detectable by EPR immediately after H2O2 addition, but decay completely after ten minutes. However, a longer-lived radical is observed at lower concentrations that is still present after 90 minutes. The monohydroxamate N-methylbutyro-hydroxamic acid (NMBH) increases the rate of decay of the fenyl species. In the presence of NMBH, none of the protein-bound free radicals are detectable; instead nitroxide radicals produced by oxidation of the hydroxamate group are observed. Similar results are observed with the trihydroxamate, desferrioxamine. "Ferryl myoglobin" is still able to initiate lipid peroxidation even after the short-lived protein free radicals are no longer detectable (E.S.R. Newman, C.A. Rice-Evans and M.J. Davies (1991) Biochemical and Biophysical Research Communications 179, 1414-1419). It is suggested that the longer-lived protein radicals described here may be partly responsible for this effect. The mechanism of inhibition of initiation of lipid peroxidation by hydroxyamate drugs, such as NMBH, may therefore be due to reduction of the protein-derived radicals, rather than reduction of ferryl haem. | lld:pubmed |
| pubmed-article:8205224 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8205224 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8205224 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8205224 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8205224 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8205224 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8205224 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8205224 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8205224 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8205224 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8205224 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8205224 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:8205224 | pubmed:issn | 1071-5762 | lld:pubmed |
| pubmed-article:8205224 | pubmed:author | pubmed-author:Wrigglesworth... | lld:pubmed |
| pubmed-article:8205224 | pubmed:author | pubmed-author:DaviesM JMJ | lld:pubmed |
| pubmed-article:8205224 | pubmed:author | pubmed-author:GreenE SES | lld:pubmed |
| pubmed-article:8205224 | pubmed:author | pubmed-author:CooperC ECE | lld:pubmed |
| pubmed-article:8205224 | pubmed:author | pubmed-author:Rice-EvansC... | lld:pubmed |
| pubmed-article:8205224 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8205224 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:8205224 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8205224 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8205224 | pubmed:pagination | 219-27 | lld:pubmed |
| pubmed-article:8205224 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8205224 | pubmed:meshHeading | pubmed-meshheading:8205224-... | lld:pubmed |
| pubmed-article:8205224 | pubmed:meshHeading | pubmed-meshheading:8205224-... | lld:pubmed |
| pubmed-article:8205224 | pubmed:meshHeading | pubmed-meshheading:8205224-... | lld:pubmed |
| pubmed-article:8205224 | pubmed:meshHeading | pubmed-meshheading:8205224-... | lld:pubmed |
| pubmed-article:8205224 | pubmed:meshHeading | pubmed-meshheading:8205224-... | lld:pubmed |
| pubmed-article:8205224 | pubmed:meshHeading | pubmed-meshheading:8205224-... | lld:pubmed |
| pubmed-article:8205224 | pubmed:meshHeading | pubmed-meshheading:8205224-... | lld:pubmed |
| pubmed-article:8205224 | pubmed:meshHeading | pubmed-meshheading:8205224-... | lld:pubmed |
| pubmed-article:8205224 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8205224 | pubmed:articleTitle | A hydrogen-donating monohydroxamate scavenges ferryl myoglobin radicals. | lld:pubmed |
| pubmed-article:8205224 | pubmed:affiliation | Department of Paediatrics, University College London Medical School, United Kingdom. | lld:pubmed |
| pubmed-article:8205224 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8205224 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8205224 | lld:pubmed |
